GlassScriptPhysician profile
Laura S Dankovich
NPI 1811492127
$7,257.46
in general payments reported to CMS, 2019-2025
52 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $518 · 2022: $1,778 · 2023: $1,385 · 2024: $1,829 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,961.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,132.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,021.70 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $746.13 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $450.30 | 2023-2025 | |
| Lilly USA, LLC | $413.45 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $304.10 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $270.64 | 2021-2024 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.95 | 2021-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $226.70 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $217.79 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $194.45 | 2022 | |
| Avvisto Therapeutics, LLC | $133.40 | 2024-2025 | Cycloset |
| Takeda Pharmaceuticals U.S.A., INC. | $124.59 | 2021-2025 | Trintellix |
| Amarin Pharma, INC. | $122.15 | 2021-2022 | |
| Amgen INC. | $116.58 | 2022-2024 | Evenity, Prolia, Repatha |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Dankovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.